Impact of the COVID-19 pandemic on the AMYPAD and EPAD projects
The worldwide COVID-19 pandemic has inevitably impacted EPAD and its sister project AMYPAD. EPAD: Most
AMYPAD
AMYPAD project published first newsletter of 2020
Welcome to the AMYPAD newsletter! Hello everyone, I thought I would look back to this
AMYPAD Prognostic and Natural History Study reaches milestone of 500 research participants
The members of the Amyloid Imaging to Prevent Alzheimer’s Disease (AMYPAD) initiative reached a significant
AMYPAD project highlights 2019
The past year was very productive and efficient for both the AMYPAD Diagnostic and Patient
Alzheimer Europe Lunch Debate focusses on improving the diagnosis of dementia
On 10 December, two Innovative Medicines Initiative projects participated in an Alzheimer Europe Lunch Debate.
Neuronet convenes annual event on European research collaboration in Alzheimer’s disease and beyond
Neuronet, a coordination and support action funded by the Innovative Medicines Initiative (IMI), brings together
Neuronet Scientific Coordination Board meeting brings together project leaders in The Hague
On 23 October (The Hague, Netherlands), Neuronet (Efficiently Networking European Neurodegeneration Research) convened the second
UNIGE is recruiting a PostDoc/PhD/Research Assistant
In a partnership with the University Hospitals of Geneva, the University of Geneva (UNIGE) is
Neuronet campaign launches on social media – Why we do what we do
Neuronet’s communication team and our community of communication representatives are pleased to announce that we will celebrate our projects.
VUmc has included its 100th participant in AMPYAD Patient Management study
A common sign of Alzheimer’s disease are deposits of a protein called beta amyloid. The